Figure 6.

Suppression of tumor angiogenesis and growth in WT mice by treatment with TCV-116, a selective AT1 receptor blocker. (a) Representative x-ray microangiograms of melanomas grown in WT mice with (right) or without (left) TCV-116. (b) A total of 10⁶ B16-F1 melanoma cells were implanted subcutaneously into 33 WT mice with (n = 17) or without (n = 16) TCV-116 (10 mg/kg/day). Tumor volumes were calculated from tumor measurements scored at the indicated postimplantation day. The growth of B16-F1 melanoma was significantly reduced and delayed in WT mice treated with TCV-116 compared with control WT mice.